HERCULES, CA – May 22, 2019 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products today announced the launch of InteliQ, a range of quality controls offered in a tube configuration that provides efficiencies in both workflow and data management. InteliQ controls are compatible with chemistry and immunoassay diagnostic platforms.*
The convenient tube configuration and barcode labeling of InteliQ offer unique sample identification and traceability as well as the simple upload of XML value assignment data. This combination of features helps to reduce hands-on time and manual errors, and it streamlines a laboratory’s workflow.
The InteliQ line of chemistry and immunoassay quality controls include: Assayed Multiqual, Cardiac Markers Plus LT, Ethanol/Ammonia, Homocysteine, Immunoassay Plus, Immunology, Specialty Immunoassay, Tumor Marker and Urine Chemistry. In addition, InteliQ users can manage their QC data and access peer group comparisons with Bio-Rad’s Unity Interlaboratory Program, which offers users greater confidence in patient results.
For more information about InteliQ, please visit www.qcnet.com/InteliQ.
*As listed in the InteliQ product insert.
Unity and Bio-Rad are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications